Business
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study Strengthened
About this update from Spyre Therapeutics, Inc.
[{"type":"image","alt":"Spyre Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Spyre Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/6cb5afc1b2c6dc162ec6de92528f922e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KjPFsJe_4q8QxBs4wAiX3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6cb5afc1b2c6dc162ec6de92528f922e","width":300,"height":73}},"lazy":false},{"type":"text","content":"On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials ","length":93,"tagName":"p"},{"type":"text","content":"Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule","length":168,"tagName":"p"},{"type":"text","content":"Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study","length":263,"tagName":"p"},{"type":"text","content":"Strengthened the balance sheet with an underwritten public offering of common stock in October 2025 and announced the appointment of Kate Tansey Chevlen as Chief Commercial Officer (CCO) ","length":186,"tagName":"p"},{"type":"text","content":"$757 million of cash, cash equivalents, and marketable securities as of December 31, 2025, with expected runway into the second half of 2028","length":145,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced its fourth quarter and full year 2025 financial results and provided program and corporate updates.","length":447,"tagName":"p"},{"type":"text","content":"“This year is a pivotal period for Spyre as we begin to unveil results from our two groundbreaking Phase 2 trials with the potential to identify multiple products that leapfrog today's...